These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 27904939)

  • 21. Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer.
    Huh JW; Kim HR; Kim YJ
    Dis Colon Rectum; 2013 Jun; 56(6):698-703. PubMed ID: 23652742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to neoadjuvant therapy in patients with early age-of-onset rectal cancer.
    Steinhagen E; Shia J; Riedel E; Nash GM; Weiser MR; Temple LK; Paty PB; Guillem JG
    Dis Colon Rectum; 2013 Jan; 56(1):58-63. PubMed ID: 23222281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study.
    Li J; Liu H; Yin J; Liu S; Hu J; Du F; Yuan J; Lv B; Fan J; Leng S; Zhang X
    Oncotarget; 2015 Dec; 6(39):42354-61. PubMed ID: 26472284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does pathologic response of rectal cancer influence postoperative morbidity after neoadjuvant radiochemotherapy and total mesorectal excision?
    Maggiori L; Bretagnol F; Aslam MI; Guedj N; Zappa M; Ferron M; Panis Y
    Surgery; 2014 Mar; 155(3):468-75. PubMed ID: 24439750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretherapeutic MRI for decision-making regarding selective neoadjuvant radiochemotherapy for rectal carcinoma: interim analysis of a multicentric prospective observational study.
    Ptok H; Ruppert R; Stassburg J; Maurer CA; Oberholzer K; Junginger T; Merkel S; Hermanek P
    J Magn Reson Imaging; 2013 May; 37(5):1122-8. PubMed ID: 23526771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
    Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
    Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Surgical Complications Following Resection of Locally Advanced Rectal Adenocarcinoma on Adjuvant Chemotherapy Delivery and Survival Outcomes.
    Jamnagerwalla M; Tay R; Steel M; Keck J; Jones I; Faragher I; Gibbs P; Wong R
    Dis Colon Rectum; 2016 Oct; 59(10):916-24. PubMed ID: 27602922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and clinical significance of cellular and acellular mucin in patients with locally advanced mucinous rectal cancer who underwent preoperative chemoradiotherapy followed by radical surgery.
    Kang CM; Lim SB; Hong SM; Yu CS; Hong YS; Kim TW; Park JH; Kim JH; Kim JC
    Colorectal Dis; 2016 Jan; 18(1):O10-6. PubMed ID: 26530997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reply to Letter: "Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies".
    Petrelli F; Barni S
    Ann Surg; 2015 Dec; 262(6):e116-7. PubMed ID: 24887979
    [No Abstract]   [Full Text] [Related]  

  • 31. Preoperative chemoradiotherapy in locally advanced rectal cancer: Ramathibodi experience.
    Sirachainan E; Sumboonnanonda K; Dangprasert S; Panvichian R; Sirisinha T; Dhanachai M; Pairachvet V; Kraiphibul P; Ratanatharathorn V
    J Med Assoc Thai; 2005 Feb; 88(2):162-7. PubMed ID: 15962665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer.
    Perez RO; São Julião GP; Habr-Gama A; Kiss D; Proscurshim I; Campos FG; Gama-Rodrigues JJ; Cecconello I
    Dis Colon Rectum; 2009 Jun; 52(6):1137-43. PubMed ID: 19581858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer: Does Time to Surgery Matter?
    Panagiotopoulou IG; Parashar D; Qasem E; Mezher-Sikafi R; Parmar J; Wells AD; Bajwa FM; Menon M; Jephcott CR
    Int Surg; 2015 Jun; 100(6):968-73. PubMed ID: 26414816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.
    Pucciarelli S; Capirci C; Emanuele U; Toppan P; Friso ML; Pennelli GM; Crepaldi G; Pasetto L; Nitti D; Lise M
    Ann Surg Oncol; 2005 Feb; 12(2):111-6. PubMed ID: 15827790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy.
    Smith FM; Wiland H; Mace A; Pai RK; Kalady MF
    Dis Colon Rectum; 2014 Mar; 57(3):311-5. PubMed ID: 24509452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation.
    Ruby JA; Leibold T; Akhurst TJ; Shia J; Saltz LB; Mazumdar M; Riedel ER; Larson SM; Guillem JG
    Dis Colon Rectum; 2012 Apr; 55(4):378-86. PubMed ID: 22426260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical complications and pathologic complete response after neoadjuvant chemoradiation in locally advanced rectal cancer.
    Duldulao MP; Lee W; Le M; Wiatrek R; Nelson RA; Chen Z; Li W; Kim J; Garcia-Aguilar J
    Am Surg; 2011 Oct; 77(10):1281-5. PubMed ID: 22127070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation.
    Probst CP; Becerra AZ; Aquina CT; Tejani MA; Wexner SD; Garcia-Aguilar J; Remzi FH; Dietz DW; Monson JR; Fleming FJ;
    J Am Coll Surg; 2015 Aug; 221(2):430-40. PubMed ID: 26206642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy.
    Hall MD; Schultheiss TE; Smith DD; Fakih MG; Wong JY; Chen YJ
    Acta Oncol; 2016 Dec; 55(12):1392-1399. PubMed ID: 27762654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.